Calibrant Biosystems, Inc. is a Gaithersburg, Maryland biotechnology company pioneering the discovery of novel protein drug targets and markers for the treatment and diagnosis of disease. Calibrant’s unique approach to protein biomarker discovery applies the proprietary Gemini™ platform to the analysis of microdissected tissue specimens, enabling targeted and comprehensive evaluation of proteins within isolated cells and their local microenvironment.

Calibrant partners with leading clinical researchers to develop new first-in-class therapeutics, beginning with the discovery of novel protein drug targets, disease pathways, and biomarkers from microdissected human tissue specimens. With an initial focus in oncology, Calibrant researchers have active development programs in a range of cancer indications including ovarian and primary brain cancer.

Calibrant also partners with pharmaceutical and biotechnology companies seeking to leverage the Gemini™ engine during the drug development process by identifying novel therapeutic targets, reducing drug development times and attrition rates, and developing targeted drugs or repositioning existing compounds on the basis of effective patient stratification.